GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guizhou Yibai Pharmaceutical Co Ltd (SHSE:600594) » Definitions » COGS-to-Revenue

Guizhou Yibai Pharmaceutical Co (SHSE:600594) COGS-to-Revenue : 0.40 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Guizhou Yibai Pharmaceutical Co COGS-to-Revenue?

Guizhou Yibai Pharmaceutical Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥200 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥501 Mil.

Guizhou Yibai Pharmaceutical Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Guizhou Yibai Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 was 60.17%.

Guizhou Yibai Pharmaceutical Co COGS-to-Revenue Historical Data

The historical data trend for Guizhou Yibai Pharmaceutical Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhou Yibai Pharmaceutical Co COGS-to-Revenue Chart

Guizhou Yibai Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.21 0.29 0.31 0.38

Guizhou Yibai Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.36 0.38 0.39 0.40

Guizhou Yibai Pharmaceutical Co COGS-to-Revenue Calculation

Guizhou Yibai Pharmaceutical Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=829.44 / 2174.032
=0.38

Guizhou Yibai Pharmaceutical Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=199.751 / 501.481
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhou Yibai Pharmaceutical Co  (SHSE:600594) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Guizhou Yibai Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 199.751 / 501.481
=60.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Guizhou Yibai Pharmaceutical Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guizhou Yibai Pharmaceutical Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Guizhou Yibai Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guizhou Yibai Pharmaceutical Co Ltd (SHSE:600594) » Definitions » COGS-to-Revenue
Comparable Companies
SHSE:600222 SHSE:603811 SZSE:300636 SZSE:002107 SZSE:002864 SZSE:300239 SZSE:300452 SZSE:300683 SZSE:300534 SHSE:603538 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
No. 220-1 Baiyun Avenue, Guiyang, Guizhou, CHN, 550008
Website
http://www.gzcci.com
Guizhou Yibai Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical products in China. Its products include tumor, cardio-cerebral vascular, respiratory system, anti-rheumatic, digestive system, pediatric, gynecological, andrological, anti-infection, anti-inflammatory, analgesic, tonic, and other drugs.
Executives
Dou Qi Ling Director
Gan Ning Director
Lang Hong Ping Director
Xia Xiao Hui senior management
Dou Ya Qi Director
Wang Zhi Wei Director
Zhu Yue Xing Director
Dai Yuan Fu senior management
Zhang Sheng Gui senior management
Feng Zhi Gang senior management
Yue Wei Director
Liu Hua Supervisors
Ye Xiang Wu Director
Jian Wei Guang Director

Guizhou Yibai Pharmaceutical Co Headlines

No Headlines